WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)
- Stroke, Acute
At a glance
- Phase
- Phase not stated
- Study type
- Interventional
- Sponsor
- Philips Clinical & Medical Affairs Global
- Enrolment target
- 594
- Started
- 23 June 2021
- Main results due
- 1 April 2027
- Study sites
- 24
- Registry updated
- 29 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Subject is 18 years of age or older, or of legal age to give informed consent per state or national law. * Baseline NIHSS score obtained prior to randomization must be equal or higher than 10 points. * Subjects with no significant pre-stroke functional disability (modified Rankin scale 0 - 2). * Subjects suspected of acute ischemic stroke with an estimated arrival time at a stroke center (clinical investigational site participating in this study) \< 6 hours from symptom onset OR wake-up stroke with time last known well of \< 12 hours and symptoms discovered within 6 hours from arrival time at a stroke center. Symptom onset is defined as point in time the patient was last known well (at baseline). * Informed consent obtained from patient or his or her legally designated representative (if locally required). * Angiography suite immediately available. * Endovascular treatment team immediately available (Neurologist, Neurointerventionalist, Anesthesiologist, Nursing, Technicians as per local standard practice) Exclusion Criteria: Clinical exclusion criteria: * Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR \> 3.0 * Known baseline platelet count \< 30.000/μL * Baseline blood glucose of \< 50mg/dL (\< 2.78mmol/l) * For patients receiving thrombolysis: severe, sustained hypertension (SBP \> 185 mm Hg or DBP \> 110 mm Hg). Note: If the blood pressure can be successfully reduced and maintained at the acceptable level using AHA/ASA guidelines recommended medication (including IV antihypertensive drips), the patient can be enrolled. * Patients from a transfer center (Primary Stroke Center) with a CT/MR that is not required to be redone in the Comprehensive Stroke Center as per discretion of the physician or per local standards (e.g. CT/MR less than 90 minutes old). * Patients in coma (NIHSS item of consciousness \>1) defined as totally unresponsive; responding only with reflexes or being areflexic (Intubated patients for transfer could be randomized only in case an NIHSS is obtained by a neurologist prior transportation). * Patients with extreme vomiting * Patients that are extremely agitated * Seizures at stroke onset which would preclude obtaining a baseline NIHSS * Serious, advanced, or terminal illness with anticipated life expectancy of less than one year. * Patients acquired stroke while in-hospital * History of life-threatening allergy (more than rash) to contrast medium * Cerebral vasculitis * Patients with a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations, mRS score at baseline must be ≤2. This excludes patients who are severely demented, require constant assistance in a nursing home type setting or who live at home but are not fully independent in activities of daily living (toileting, dressing, eating, cooking and preparing meals, etc.) * Unlikely to be available for 90-day follow-up (e.g. no fixed home address, visitor from overseas). * Patients with unstable clinical status who require emergent life support care * Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study. * Subject participates in a potentially confounding drug or device trial during the course of the study. * Woman of childbearing potential who is known to be pregnant on admission. * Subject meets an exclusion criteria according to national law (e.g. age, pregnant woman, breast feeding woman) * Subject is Philips employee or their family members residing with this Philips employee.
What this study is about
In the sponsor’s own words, from the registry.
The WE-TRUST study is a multi-center randomized clinical trial to assess the impact of a Direct to Angio Suite (DTAS) workflow on stroke patient outcomes.
Study sites(24)
Baptist Medical Center
Jacksonville, Florida, United States
Recruiting
Grady Memorial Hospital/Emory University
Atlanta, Georgia, United States
Not yet recruiting
Montefiore Medical Center
The Bronx, New York, United States
Recruiting
La Sagrada Familia Clinic
José Hernández, Argentina
Recruiting
UZ Brussels
Brussels, Belgium
Recruiting
Hospital Geral de Fortaleza
Fortaleza, Brazil
Recruiting
Hospital de Base
São José do Rio Preto, Brazil
Not yet recruiting
Hospital Estadual Central - Fundação Estadual de Inovação em Saúde - Inova Capixaba
Vitória, Brazil
Recruiting
Hospices Civils de Lyon
Lyon, France
Completed
CHU Montpellier
Montpellier, France
Recruiting
Bicêtre Hospital
Paris, France
Recruiting
University Hospital Bonn (UKB Universitätsklinikum Bonn)
Bonn, Germany
Recruiting
Klinikum Kassel
Kassel, Germany
Recruiting
Universitätsklinikum Schleswig-Holstein Lübeck
Lübeck, Germany
Recruiting
Klinikum rechts der Isar der TU München
Munich, Germany
Recruiting
St. Antonius Ziekenhuis
Nieuwegein, Netherlands
Completed
Haaglanden Medical Center
The Hague, Netherlands
Withdrawn
University Emergency Hospital Bucharest
Bucharest, Romania
Recruiting
Hospital Clinico San Carlos
Madrid, Moncloa - Aravaca, Spain
Recruiting
Vall d'Hebron University Hospital
Barcelona, Spain
Recruiting
Hospital Universitari Doctor Josep Trueta de Girona
Girona, Spain
Recruiting
Hospital Virgen del Rocio
Seville, Spain
Recruiting
İstanbul Aydin University medical park florya hospital
Istanbul, Turkey (Türkiye)
Completed
İstinye Üniversitesi Gaziosmanpaşa Hastanesi
Istanbul, Turkey (Türkiye)
Not yet recruiting
Showing 24 of 24 sites. 17 of the 24 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT04701684. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me